HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.

AbstractBACKGROUND:
In a preliminary dose-finding study, D-cycloserine, a partial agonist at the glycine modulatory site of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, improved negative symptoms and cognitive function when added to conventional neuroleptics at a dose of 50 mg/d.
METHODS:
Forty-seven patients with schizophrenia meeting criteria for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to their conventional neuroleptic for an 8-week, double-blind trial. Clinical assessments were performed at baseline and at weeks 1, 2, 4, 6, and 8. Serum concentrations of D-cycloserine, relevant amino acids, and homovanillic acid were assayed at baseline and at weeks 4 and 8. A cognitive battery was performed at baseline and at week 8.
RESULTS:
Thirty-nine patients completed the 8-week trial. Seven dropouts occurred in the D-cycloserine group and 1 in the placebo group. The mean reduction in negative symptoms with D-cycloserine (23%) was significantly greater than with placebo (7%) as calculated by slopes representing Scale for the Assessment of Negative Symptoms (SANS) total scores. Improvement of negative symptoms was predicted by low neuroleptic dose and low baseline SANS total score. No differences were found in performance on any cognitive test between groups or in changes in any other clinical measure. Clinical response did not correlate significantly with serum amino acid concentrations at baseline or with concentrations of D-cycloserine at weeks 4 and 8.
CONCLUSION:
These results support the hypothesis that agents acting at the glycine modulatory site of the NMDA receptor improve primary negative symptoms.
AuthorsD C Goff, G Tsai, J Levitt, E Amico, D Manoach, D A Schoenfeld, D L Hayden, R McCarley, J T Coyle
JournalArchives of general psychiatry (Arch Gen Psychiatry) Vol. 56 Issue 1 Pg. 21-7 (Jan 1999) ISSN: 0003-990X [Print] UNITED STATES
PMID9892252 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Amino Acids
  • Antipsychotic Agents
  • Placebos
  • Receptors, N-Methyl-D-Aspartate
  • Cycloserine
  • Glycine
Topics
  • Adult
  • Amino Acids (blood)
  • Antipsychotic Agents (therapeutic use)
  • Cycloserine (blood, therapeutic use)
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Glycine (blood, physiology)
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Placebos
  • Psychiatric Status Rating Scales
  • Receptors, N-Methyl-D-Aspartate (drug effects, physiology)
  • Schizophrenia (diagnosis, drug therapy, physiopathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: